

13/2/23

Total No. of printed pages = 2

MPL 103 T

BINA CHOWDHURY CENTRAL LIBRARY
(GIMT & GIPS)
Azara, Hatkhôwâpara
Guwahati - 781017

Roll No. of candidate

--	--	--	--	--	--	--	--	--	--

2023

M.Pharm. 1st Semester End-Term Examination

PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS - I

(New Regulation)

Full Marks – 75

Time – Three hours

The figures in the margin indicate full marks for the questions.

SECTION – A

1. Answer *all* the questions : (10 × 2 = 20)
- (a) Nootropics
 - (b) Immunosuppressant
 - (c) Angina
 - (d) COPD
 - (e) Rota rod apparatus
 - (f) Metastasis
 - (g) Sprague-Dawley rats
 - (h) Insulin
 - (i) Eddy's Hot Plate method
 - (j) Metabolic cage.

SECTION – B

2. Answer any *seven* questions : (7 × 5 = 35)
- (a) Explain any one model for screening hepatoprotective agents.
 - (b) Explain any one model for screening anti-inflammatory agents.
 - (c) Write a brief note on applications of different species and strains of animals.

[Turn over

- (d) Write a brief note on maintenance and breeding of laboratory animals.
- (e) Explain any one model for screening immunomodulators agents.
- (f) Elaborate on the immunoassay for digoxin.
- (g) Discuss in detail the limitations of animal experimentation.
- (h) Enumerate the models for screening of antianginal activity and explain the isolated Langendorff technique.
- (i) Explain the general principles of immunoassay.

SECTION – C

3. Answer any *two* questions: (2 × 10 = 20)
- (a) List out the commonly used methods to screen any new substances for antidiabetic activity. Discuss one *in-vivo* and *in-vitro* method.
 - (b) Enumerate the various pre-clinical models for screening antihypertensive agents. Explain any two models.
 - (c) Enumerate the various pre-clinical models for screening analgesic agents.